
Aakash Desai/LinkedIn
Mar 2, 2025, 11:45
Aakash Desai: Excited to be at the 4th Annual Driver Alterations and Targeted Therapies in Advanced NSCLC in India
Aakash Desai, Associate Director of Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, shared a post on LinkedIn:
“Excited to be a speaker at the 4th Annual Driver Alterations and Targeted Therapies in Advanced NSCLC in Chandigarh, India!
I’ll be debating optimal sequencing of therapies for EGFR-mutated NSCLC, diving into the role of upfront monotherapy vs. combination strategies and what it means for patient outcomes.
Looking forward to insightful discussions and learning from colleagues advancing lung cancer care!”
More posts featuring Aakash Desai.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 2, 2025, 10:50
Mar 2, 2025, 10:22
Mar 2, 2025, 10:05
Mar 2, 2025, 10:02
Mar 2, 2025, 09:53
Mar 2, 2025, 09:47
Mar 2, 2025, 09:20